Grandfield & Dodd, LLC
- SEC CIK
- 0001308016
- Latest filing
- Aug 7, 2026
REGN holding history
Regeneron Pharmaceuticals, Inc. in every 13F filed by Grandfield & Dodd, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
REGN overviewAll 13F holders of REGNFull Q2 2026 holdings
- Shares (Q2 2026)
- 36,628
- Value
- $22.8M
- % of portfolio
- 1.2%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 36,628 | $22.8M | 1.2% | +213+0.6% | Added | Holders |
| Q1 2026 | 36,415 | $28.1M | 1.6% | −153−0.4% | Reduced | Holders |
| Q4 2025 | 36,568 | $28.2M | 1.6% | +117+0.3% | Added | Holders |
| Q3 2025 | 36,451 | $20.5M | 1.2% | +1,246+3.5% | Added | Holders |
| Q2 2025 | 35,205 | $18.5M | 1.1% | +1,998+6.0% | Added | Holders |
| Q1 2025 | 33,207 | $21.1M | 1.3% | +611+1.9% | Added | Holders |
| Q4 2024 | 32,596 | $23.2M | 1.4% | +268+0.8% | Added | Holders |
| Q3 2024 | 32,328 | $34.0M | 2.0% | −80.0% | Reduced | Holders |
| Q2 2024 | 32,336 | $34.0M | 2.2% | +59+0.2% | Added | Holders |
| Q1 2024 | 32,277 | $31.1M | 2.0% | +75+0.2% | Added | Holders |
| Q4 2023 | 32,202 | $28.3M | 2.0% | −40−0.1% | Reduced | Holders |
| Q3 2023 | 32,242 | $26.5M | 1.9% | +763+2.4% | Added | Holders |
| Q2 2023 | 31,479 | $22.6M | 1.6% | +554+1.8% | Added | Holders |
| Q1 2023 | 30,925 | $25.4M | 1.8% | +449+1.5% | Added | Holders |
| Q4 2022 | 30,476 | $22.0M | 1.6% | +204+0.7% | Added | Holders |
| Q3 2022 | 30,272 | $20.9M | 1.7% | +998+3.4% | Added | Holders |
| Q2 2022 | 29,274 | $17.3M | 1.4% | +500+1.7% | Added | Holders |
| Q1 2022 | 28,774 | $20.1M | 1.4% | +977+3.5% | Added | Holders |
| Q4 2021 | 27,797 | $17.6M | 1.1% | +1,766+6.8% | Added | Holders |
| Q3 2021 | 26,031 | $15.8M | 1.1% | +4,395+20.3% | Added | Holders |
| Q2 2021 | 21,636 | $12.1M | 0.8% | +3,074+16.6% | Added | Holders |
| Q1 2021 | 18,562 | $8.78M | 0.7% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.